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Abstract
Because the therapeutic use of the antitumor ether lipid 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine
 .ET-18-OCH is restricted by its hemolytic activity we explored the use of lipid packing parameters to reduce this toxicity3
by creating structurally optimized ET-18-OCH liposomes. We postulated that combination of ET-18-OCH , which is3 3
similar in structure to lysophosphatidylcholine, with lipid molecules of complementary molecular shape opposite
.headgrouprchain volume would likely yield a stable lamellar phase from which ET-18-OCH exchange to red blood cell3
membranes would be curtailed. To quantitate the degree of shape complementarity, we used a Langmuir trough and
 .measured the mean molecular area per molecule MMAM for monolayers comprised of ET-18-OCH , the host lipids, and3
binary mixtures of varying mole percentage ET-18-OCH . The degree of complementarity was taken as the reduction in3
MMAM from the value expected based on simple additivity of the individual components. The greatest degree of shape
complementarity was observed with cholesterol: the order of complementarity for the ET-18-OCH -lipid mixtures examined3
was cholesterol))DOPE)POPCfDOPC. Phosphorus NMR and TLC analysis of aqueous suspensions of ET-18-OCH3
 .40 mol% with the host lipids revealed them to all be lamellar phase. For ET-18-OCH at 40 mol% in liposomes, the3
hemolytic activity followed the trend of the reduction in MMAM and was least for the ET-18-OCH rcholesterol system3
 .  .H s661 mM ET-18-OCH followed by ET-18-OCH rDOPE H s91 mM and mixtures with POPC and DOPC50 3 3 50
which were comparable at H s26 mM and 38 mM, respectively: the H concentration for free ET-18-OCH was 1650 50 3
mM. This experimental strategy for designing optimized liposomes with a reduction in exchange, and hence toxicity, may
be useful for other amphipathicrlipophilic drugs that are dimensionally compatible with lipid bilayers. q 1997 Elsevier
Science B.V.
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1. Introduction
The ether lipid 1-O-octadecyl-2-O-methyl-sn-
 .glycero-3-phosphorylcholine ET-18-OCH has3
demonstrated antitumor activity in both in vitro and
w xin vivo studies 1–3 and has undergone evaluation
w x clinically 4 . Although the mechanisms likely multi-
.factorial for the tumoricidal activity of ET-18-OCH3
in vivo remain unclear it is well established that for
i.v. administration hemolysis is a primary dose-limit-
w xing toxicity 4 .
The disruptive effect of ET-18-OCH upon red3
cells may be explained for the most part by its
structural similarity to lysophosphatidylcholine
 .lysoPC . In solution ET-18-OCH organizes into3
w xmicelles above a critical concentration of 0.5 mM 5 .
In these dynamic structures ET-18-OCH is free to3
exchange with biological membranes where it likely
disrupts lipid–lipid and lipid–protein packing.
One approach to reduce the availability, and hence
toxicity, of amphipathic compounds has been to in-
corporate these compounds into lipid based carrier
 w x w x.systems i.e., liposomes 6 , lipid complexes 7,8 .
To successfully incorporate ET-18-OCH into liposo-3
mal membranes, its detergent nature, derived from its
molecular shape, must be considered in order to
 .choose the appropriate carrier lipid s . The molecular
shape i.e., volume and cross-sectional area of polar
.to nonpolar regions of lipids dictates whether they
form micelles, lamella, or inverted micellar hexago-
. w xnal I and II structures 9 . Several investigators have
shown that lysoPC, which adopts micellar structure,
forms lamellar structures when combined with lipids
of opposite polarrnonpolar shape due to complemen-
w xtary side-by-side packing 10–13 .
In this study, we examined ET-18-OCH in com-3
bination with lipids expected to complement its
molecular shape in order to design a stable liposome
system from which the exchange of ET-18-OCH3
would be curtailed. To assess side-by-side packing
we used a Langmuir trough to determine the mean
 .molecular area per molecule MMAM for mixtures
of ET-18-OCH with other lipids in monolayer films.3
Considering the reduction in MMAM degree of shape
.complementarity , we formulated liposomes with ET-
 .18-OCH and host lipid 40 mol% ET-18-OCH3 3
and found a correlation between the shape comple-
mentarity of the monolayer films and the hemolytic
activity of the corresponding liposome systems. Im-
portantly, the monolayer work indicated that ET-18-
OCH experienced significantly greater shape com-3
plementarity, concomitant with a much reduced
hemolytic activity, when combined with cholesterol
than when combined with dioleoylphos -
 .phatidylethanolamine DOPE , a scenario not ex-
pected from previous literature as both lipids form
w xlamellar structures with lysoPC 9–13 . This strategy
to measure shape complementarity may be useful for
the incorporation of other amphipathicrlipophilic
compounds into liposomerlipid-based carrier sys-
tems, especially where reasonably high drug to lipid
ratios are desired in order to reduce lipid dosing.
2. Materials and methods
2.1. Materials
All phospholipids were purchased from Avanti
 .Polar Lipids Alabaster, Alabama . ET-18-OCH was3
purchased from either Avanti Polar Lipids or from
Alexis Corporation of San Diego, California used
.only for the NMR studies . Our own testing indicated
that both materials were )99% pure HPLC, data
.not shown . Cholesterol was purchased from Sigma
 .Chemical Co. St. Louis, MO . All lipids and reagents
were of the highest purity available.
2.2. Monolayer studies
 .The mean molecular area per molecule MMAM
of ET-18-OCH formulations was determined using a3
Langmuir-Blodgett mini-trough equipped with a dual
barrier mechanism and a Wilhelmy balance, all from
 .KSV Instruments Trumbull, Connecticut . ET-18-
OCH formulations were prepared from lipid pow-3
ders that were dissolved in a solvent system of
hexane:ethanol 9:1, assayed and then combined. Sin-
gle lipid solutions and mixtures were made to contain
an overall lipid concentration of approximately 1.5
mM which was quantitated precisely by phosphate
w x w x14 and cholesterol assays 15 . Monolayers were
formed by drop-wise addition of sample on to the
aqueous surface 10 mM Hepes, 150 mM NaCl buffer,
.pH 7.2 at the center of the trough. Sample was
added until the surface pressure just started to rise
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above zero, at which time the exact volume of sample
added was recorded. After waiting 3 min for solvent
evaporation and the monolayer to stabilize, the sur-
face area was reduced at a rate of 15 cm2rmin and
surface pressure recorded. The solution level was
maintained 1 mm below the top edge of the trough to
avoid leakage; contact was maintained with the barri-
 .ers composed of Delrin due to their hydrophilic
nature. The MMAM obtained by extrapolating the
steepest portion of the pressure-area curve to the
value at zero surface pressure represented the value
A . The highest collapse pressure measured for anyo
 .lipid in this study F47 mNrm was well below the
values we were able to attain with disaturated PC
 .molecules )62 mNrm , indicating that it was not
an artifactual consequence of a technical limitation.
All experiments were done at 238C.
2.3. Liposome preparation
Liposomes were prepared by first mixing the ap-
propriate lipids in solvent, drying the lipid to a thin
film using vacuum rotary evaporation, and hydrating
the resulting film with buffer solution 10 mM Hepes,
.150 mM NaCl, pH 7.4 . The resulting dispersions
were used without further processing for NMR stud-
ies. For hemolysis studies, the lipid dispersions were
then repeatedly extruded through polycarbonate Nu-
clepore membranes Nuclepore Corp., Pleasanton,
.CA of defined pore size. Liposomes were first passed
10 times through a membrane of 0.2 mm pore size
and then passed 10 times through a membrane of 0.1
mm pore size. For ET-18-OCH rcholesterol, the3
mixtures were first passed through a 0.4 mm pore
size filter 10 times before proceeding to the 0.2 mm
pore size filter and finally the 0.1 mm pore size filter.
Liposome size was determined by quasi-elastic light
scattering using a Nicomp Model 270r370 Submi-
cron Particle Sizer from Pacific Scientific Menlo
.Park, CA ; mean diameters via a number weighted
distribution are reported.
2.4. Hemolysis
Hemolysis was assessed as previously described
w x16 . Each sample was serially diluted with buffer
solution and 0.3 ml of each diluted solution was
mixed with 0.3 ml of washed human red blood cells
w  .x4% in PBS vrv . For controls, 0.3 ml of the red
blood cell suspension was mixed with either 0.3 ml
 .of buffer solution negative hemolysis control or 0.3
 .ml of distilled water positive hemolysis control .
Samples and standards were placed in a 378C incuba-
tor and agitated for 20 h. Tubes were centrifuged at
 .low speed 2000=g for 10 min to pellet RBCs.
Two hundred ml of the supernatant was removed and
mixed with 1 ml of water. Hemolysis was quantitated
by absorbance at 550 nm using a Shimadzu 2101
UV-Vis Scanning Spectrophotometer Shimadzu
.Corp., Kyoto, Japan . One hundred percent hemolysis
was defined as the maximum amount of hemolysis
obtained from free ET-18-OCH .3
( )2.5. Phosphorus nuclear magnetic resonance NMR
spectroscopy
Spectra were obtained at 121.51 MHz on a Bruker
AC300 NMR Spectrometer Bruker Instruments, Bil-
.lerica, MA at either 238C or 378C. 16K points were
acquired with a sweep width of 42 kHz using a 6 ms
90 degree pulse. The average of 3500 acquisitions
was processed with 50 Hz line broadening. Samples
contained a total of 38 mM ET-18-OCH approxi-3
.mately 60 mgrml total lipid except for the ET-18-
OCH rcholesterol mixtures which contained 76 mM3
 .ET-18-OCH 60–90 mgrml total lipid .3
( )2.6. Thin-layer chromatography TLC
Aqueous samples were first mixed with methanol
and chloroform in the ratio 0.8:2:1 to form a single
monophase. An aliquot of this was then applied to a
s ilic a g e l p la te w h ic h w a s ru n in
 .chloroformrmethanolrwater 65:25:4 and then de-
veloped with iodine vapor. Standards of each lipid
were also run.
3. Results and discussion
To design a liposomal membrane that will accom-
modate ET-18-OCH and minimize its exchange to3
other membranes, the molecular shape of ET-18-
OCH and the host lipid must complement one an-3
other or other than ideal side-by-side packing will
 . w xoccur see Fig. 1 . As discussed by Kumar 9 ,
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molecular shape can be described theoretically based
upon geometry, hydration, molecular motion, and
other considerations. A dimensionless packing pa-
 .rameter SsVral has been described which defines
lipid molecules in terms of headgroup area at the
 .  .  .interface a and the volume V and length l of the
w xhydrocarbon region 9,17 . Because it has a phospho-
choline headgroup and a single chain, ET-18-OCH3
would be characterized by this analysis as having an
 .inverted cone shape, like lysoPC S-0.74 , and is
therefore expected to form micelles, which it does
 w x.  .CMCs0.5 mM, 5 . Phosphatidylcholine PC , for
 .example, is considered to be cylindrical Sf0.75–1 ,
consistent with its ability to form lamella, and DOPE
 .is considered cone-shaped S)1 , thus explaining
why it forms inverted micellar structures hexagonal
. w xII phase 18 .
To determine which lipids would combine best
with ET-18-OCH , and in what molar ratio, we3
employed a Langmuir trough to measure mean
molecular area per molecule for lipids deposited as a
monolayer film. As illustrated in Fig. 1, for those
lipids that would complement the shape of ET-18-
 .OCH cone , the MMAM for the mixture would be3
less than that expected from simple addition of the
values for the individual components. That is, the
 .expected MMAM A based on additivity can be0
expressed for a two component system as
A sX PA qX PA 1 .0 1 1 2 2
where X is the mol fraction of each component and
A and A are the MMAMs measured for the indi-1 2
w xvidual lipids 19 . The magnitude of the deviation
from this value then reflects the degree to which
shape complementarity occurs inclusive would be
.motional restrictions, changes in hydration, etc. .
First we obtained the area versus surface pressure
profiles for ET-18-OCH and several lipids we wished3
w  .to test cholesterol, 1-palmitoyl-2-oleoyl-PC POPC ,
 . xdioleoyl-PC DOPC , and DOPE . Cholesterol and
DOPE were chosen because both have an inverted
cone-shape and it had been shown previously from
NMR and X-ray studies that those lipids form lamel-
w xlar phase structures when mixed with lysoPC 10–12 .
The area-pressure diagrams are shown in Fig. 2. As
the surface area was reduced surface pressure in-
creased as the lipids packed into an organized ori-
ented monolayer, each characteristic for that lipid. At
high surface pressure, collapse of monolayers oc-
curred where material was lost into the aqueous
subphase. As expected, the profile for ET-18-OCH3
w xwas similar to that observed for lysoPC 20 with a
 .collapse pressure 37 mNrm lower than that ob-
 .served for the other lipids. MMAMs A were deter-0
mined for each lipid by extrapolation of the steepest
portion of the curves to the value at zero surface
pressure. These values are listed in the legend to Fig.
2.
We next measured MMAMs for ET-18-OCH3
mixed at various mole ratios with each of the other
Fig. 1. Schematic representation of how molecular shape affects collective organization. Dark regions symbolize polar domains. The
 .  .  .  . packing parameter S relates the area of the polar headgroup a and the volume V and length l of the hydrocarbon region see Kumar
w x .9 for further details .
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Fig. 2. Surface pressure versus mean molecular area per molecule
for monolayer films of individual lipids. Lipids are ET-18-OCH3
 .  .  .  .  .a , cholesterol b , POPC c , DOPC d , and DOPE e . Films
were compressed at 15 cm2rmin. Each curve is the average of
three compressions. A values determined as described in Sec-0
˚
2
˚
2.tion 2.2 were 77.8 A for ET-18-OCH , 44.8 A cholesterol,3
˚
2
˚
2
˚
281.7 A for POPC, 82.0 A for DOPC, and 82.3 A for DOPE.
 .lipids Fig. 3 . From the collapse pressures and pres-
sure-area curves there appeared to be complete misci-
bility for these binary systems. For ET-18-
OCH rcholesterol mixtures, the deviation from A3 0
 .represented as the dashed line was significant with
˚
2a MMAM that was ;25 A less than that expected
for ET-18-OCH and cholesterol at a 1:1 molar ratio3
 .  .Fig. 3, top . Shown in Fig. 3 bottom are the
differences between experimentally derived MMAM
 .A and A expressed as a percentage of A :exp 0 0
A yA0 exp%reductions P100 2 . /A0
The order for the percent reductions in MMAM for
lipids mixed with ET-18-OCH was cholesterol)3
DOPE)POPC)DOPC. These results were not sur-
prising given that both DOPE and cholesterol possess
w xan inverted cone shape 10,11 . However, what is
surprising is the much larger reduction afforded the
ET-18-OCH rcholesterol mixture as compared to3
ET-18-OCH rDOPE. Interestingly, for DOPE,3
DOPC, and POPC, the maximum reduction was noted
at 40 mol% ET-18-OCH , while for cholesterol the3
profile was roughly symmetric about its maximum at
50 mol% ET-18-OCH .3
With the degree of shape complementarity estab-
lished, we next prepared liposome suspensions for
assessment of hemolytic activity. First, we examined
the phosphorus NMR signal of hydrated handshaken
dispersions for the ET-18-OCH rlipid systems to3
 .confirm the existence of lamellar phase see Fig. 4 .
The phosphorus NMR spectra for ET-18-OCH at 403
mol% with both cholesterol and DOPE at 238C and
w x378C were typical of lamellar phase 21 . For DOPC
and POPC mixtures with ET-18-OCH , there was an3
additional isotropic component on top of the broader
lamellar signature. The spectrum resembled that for
w xmixtures of small and large liposomes 22 and the
Fig. 3. Top panel: Mean molecular area per molecule as a
function of ET-18-OCH content where monolayers were formed3
 . from ET-18-OCH mixed with DOPC circles , POPC up trian-3
.  .  .gles , DOPE squares , or cholesterol inverted triangles . Data
are the average of 3 experiments"S.D. The dashed line repre-
 .sents the expected values A for cholesterolrET-18-OCH0 3
mixtures based on simple additivity of the individual values of
 .MMAM see text . The magnitude of the deviation from this
curve indicates the degree of shape complementarity. A curves0
for the other lipids were omitted for clarity. Bottom panel:
Percent reduction in MMAM as a function of ET-18-OCH see3
 ..Eq. 2 .
( )W.R. Perkins et al.rBiochimica et Biophysica Acta 1327 1997 61–6866
Fig. 4. Phosphorus NMR of ET-18-OCH mixtures at various3
 . mol ratios with other lipids: a ET-18-OCH rcholesterol 60:403
.  .  .mol ratio at 238C; b ET-18-OCH rcholesterol 50:50 at3
 .  .  .238C; c ET-18-OCH rcholesterol 40:60 at 238C; d ET-18-3
 .  .OCH rcholesterol 40:60 at 378C; e ET-18-OCH rPOPC3 3
 .  .  .  .40:60 at 238C; f ET-18-OCH rDOPC 40:60 at 238C; g3
 .  .ET-18-OCH rDOPE 40:60 at 238C; and h ET-18-3
 .  .OCH rDOPE 40:60 at 378C. The isotropic peak of a was3
assigned the value of 0 ppm.
line width appeared to be too broad 3.6–3.9 ppm at
. w xhalf height to be ET-18-OCH micelles 23 . How-3
ever, we could not rule out large mixed micellar
structures. To determine whether this component was
due to mixed micellar structures or small vesicular
structures, we collected the fraction that would not
form a plug on top of the solution the mixtures
.floated upon centrifugation and examined the ratio
of ET-18-OCH to lipid by TLC see Section 2 for3
.  .details . The ratios determined by TLC were essen-
tially the same as that for the bulk sample, indicating
that the structures were small liposomes and not
ET-18-OCH -enriched micellar structures data not3
.shown .
While the MMAM was comparable for ET-18-
OCH mixtures with cholesterol at 40, 50, and 603
 .mol% Fig. 3B , NMR revealed only the 40 mol%
ET-18-OCH mixture to be completely lamellar Fig.3
.4c . As the ET-18-OCH rcholesterol ratio was in-3
creased a narrow isotropic signal became more
prominent. Given its narrow line width 0.48–0.95
.ppm at half height this signal most likely arose from
micellar structures. In fact, previous work had indi-
cated that the limit for lysoPC in lysoPCrcholesterol
w xliposomes was near 50 mol% 23 .
We next proceeded to make liposomes containing
40 mol% ET-18-OCH for hemolysis testing. All3
liposomes were prepared by extrusion to assure uni-
form size distribution. While extrusion was more
 .difficult higher pressure required for the ET-18-
OCH rcholesterol mixture, which had a final size3
distribution 77 nm by light scattering – number
.weighting slightly larger than that for the other
 .samples 40 nm , the ratio of lipids in the final
preparation was not different from that found prior to
extrusion. Samples were next incubated with washed
human red blood cells and hemolysis quantitated as
described in Section 2. Shown in Fig. 5 are the
hemolysis profiles for the four ET-18-OCH lipo-3
some preparations, as well as free ET-18-OCH .3
Hemolysis was least for the ET-18-OCH rcholesterol3
formulation with the concentration of ET-18-OCH3
 .that yielded 50% hemolysis H at 661 mM ET-18-50
OCH . This formulation was over 7 times less3
hemolytic than the next closest formulation which
Fig. 5. Hemolytic activity of ET-18-OCH incorporated in lipo-3
somes formed by extrusion through a 100 nm pore size filter.
 .Symbols represent free ET-18-OCH diamonds , and ET-18-3
OCH incorporated at 40 mol% into liposomes with the co-lipids3
 .  .  .POPC circles , DOPC up triangles , DOPE squares , and
 .cholesterol inverted triangles . Each preparation was run in
triplicate and the error bars represent S.D. Liposome size was
measured by dynamic light scattering and found to be approxi-
mately 40 nm for samples except ET-18-OCH rcholesterol3
which had a mean diameter of 77 nm.
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was ET-18-OCH rDOPE with a H of 91 mM. The3 50
DOPC and POPC ET-18-OCH formulations were3
 .similar H of 38 and 26 mM, respectively and not50
far above the H value for free ET-18-OCH H s50 3 50
.16 mM .
We subsequently compared the hemolytic activity
of ET-18-OCH small unilamellar vesicles formu-3
lated at 40 or 60 mol% with cholesterol and found
that the 60 mol% material was as hemolytic as free
 .ET-18-OCH data not shown . This confirmed our3
w xsuspicion that ET-18-OCH , like lysoPC 9,23 , does3
not form stable liposome structures above a 1:1 stoi-
chiometry. This also indicated that the degree of
shape complementarity in planar monolayers in no
way predicts how molecules organize in solution. For
the 40 mol% ET-18-OCH formulations examined3
here, however, lamellar structure was confirmed by
31P-NMR.
While it was not surprising that the degree of
shape complementarity, and hemolysis, for ET-18-
OCH with cholesterol and DOPE was better than3
that for ET-18-OCH with POPC and DOPC, it was3
surprising that the cholesterol system was so signifi-
cantly better than the DOPE system. Considering
their similar theoretical packing parameters Ss1.2–
w x.1.3 9 , one might have expected both lipids to pack
equally well with ET-18-OCH . However, one must3
keep in mind that the theoretical packing parameter
does not consider the favorable interactive effects of
mixing two different lipids. That is, it does not
predict alterations in hydration, chain motion, etc.,
that one lipid might invoke in another or mutual
alterations as a consequence of mixing. The contribu-
tions of these ‘shape’-altering effects would, how-
ever, be measured experimentally, as we have
demonstrated here. Because lamellar phase was ob-
served at both 238 and 378C for both cholesterol and
DOPE formulations, we do not believe the differ-
ences between the two systems can be attributed to
non-ideal mixing in the ET-18-OCH rDOPE system,3
 .  .as micellar ET-18-OCH or hexagonal II DOPE3
phase signatures would have been apparent.
In conclusion, because hemolysis is a significant
w xtoxicity for i.v. administration of ET-18-OCH 4 ,3
liposomal incorporation would seem to be an ideal
solution. However, without consideration of lipid
packing the result might be a formulation with little
or no gain over free drug e.g., the POPC and DOPC
.systems examined here . Additionally, incorporation
of drug into liposomes at relatively low mole percent-
 .ages e.g., 1–5 mol% may present a problem later
when total lipid dosing may become an issue. Here,
we assessed side-by-side packing of ET-18-OCH3
with lipids expected to complement its molecular
shape using monolayers spread onto a Langmuir
trough. For the systems studied, ideal packing was
observed at relatively high mol percentages of ET-
 .18-OCH 40 mol% . We then compared the order of3
shape complementarity of the monolayer films, the
reduction in MMAM, to the hemolytic activity of the
 .corresponding ET-18-OCH 40 mol% liposomes3
and found a correlation between the two. Importantly,
we identified a mixture with a significantly reduced
hemolytic activity ET-18-OCH rcholesterol, H3 50
. 661 mM as compared to free ET-18-OCH H 163 50
.mM . Presumably this reduction in hemolysis reflects
the ability of the carrier system to accommodate
ET-18-OCH thus curtailing its exchange to other3
membranes. Using shape complementarity, it may be
possible to identify other lipid candidates for combi-
nation with ET-18-OCH or incorporate other amphi-3
pathicrlipophilic drugs e.g., ET-18-OCH analogs3
w x.24 into liposomerlipid based carrier systems with
 .similar reductions in exchange toxicity for these
agents.
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